COMPASS Pathways plc (NASDAQ:CMPS) Receives Consensus Recommendation of "Buy" from Brokerages

COMPASS Pathways plc (NASDAQ:CMPS - Get Free Report) has earned an average recommendation of "Buy" from the six ratings firms that are covering the firm, Marketbeat reports. Six research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $33.60.

Several equities analysts have recently commented on CMPS shares. Cantor Fitzgerald reissued an "overweight" rating on shares of COMPASS Pathways in a report on Monday, September 9th. HC Wainwright decreased their price target on shares of COMPASS Pathways from $120.00 to $60.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. Maxim Group cut their price objective on COMPASS Pathways from $22.00 to $12.00 and set a "buy" rating for the company in a research report on Friday, November 1st. Finally, Royal Bank of Canada decreased their target price on COMPASS Pathways from $23.00 to $18.00 and set an "outperform" rating on the stock in a research report on Friday, November 1st.

Insider Activity at COMPASS Pathways

In related news, major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of the stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $6.05, for a total transaction of $16,093,000.00. Following the sale, the insider now owns 6,905,774 shares in the company, valued at approximately $41,779,932.70. This represents a 27.81 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 4.25% of the stock is owned by insiders.

Hedge Funds Weigh In On COMPASS Pathways

A number of large investors have recently made changes to their positions in CMPS. Blue Trust Inc. bought a new stake in COMPASS Pathways in the second quarter worth about $81,000. Green Alpha Advisors LLC bought a new stake in shares of COMPASS Pathways during the 3rd quarter worth approximately $99,000. Y Intercept Hong Kong Ltd bought a new stake in shares of COMPASS Pathways during the 3rd quarter worth approximately $131,000. Fore Capital LLC purchased a new position in COMPASS Pathways during the 2nd quarter valued at $181,000. Finally, Geode Capital Management LLC grew its position in COMPASS Pathways by 160.3% in the 3rd quarter. Geode Capital Management LLC now owns 42,169 shares of the company's stock valued at $266,000 after acquiring an additional 25,970 shares during the last quarter. 46.19% of the stock is owned by hedge funds and other institutional investors.

COMPASS Pathways Stock Performance

Shares of NASDAQ:CMPS traded up $0.05 during midday trading on Friday, reaching $3.97. 1,169,654 shares of the company's stock traded hands, compared to its average volume of 638,571. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91. COMPASS Pathways has a one year low of $3.86 and a one year high of $12.75. The company has a market cap of $271.63 million, a price-to-earnings ratio of -1.80 and a beta of 2.24. The stock has a 50 day moving average of $5.07 and a 200 day moving average of $6.24.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.60) by $0.04. During the same period in the previous year, the company earned ($0.67) earnings per share. As a group, equities research analysts anticipate that COMPASS Pathways will post -2.33 EPS for the current fiscal year.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.